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Abstract
Background: Virotherapy represents a promising approach for ovarian cancer. In this regard, conditionally
replicative adenovirus (CRAd) has been translated to the context of human clinical trials. Advanced design of CRAds
has sought to exploit their capacity to induce anti-tumor immunization by configuring immunoregulatory molecule
within the CRAd genome. Unfortunately, employed murine xenograft models do not allow full analysis of the
immunologic activity linked to CRAd replication.
Results: We developed CRAds based on the Ad5/3-Delta24 design encoding cytokines. Whereas the encoded
cytokines did not impact adversely CRAd-induced oncolysis in vitro, no gain in anti-tumor activity was noted in
immune-incompetent murine models with human ovarian cancer xenografts. On this basis, we explored the
potential utility of the murine syngeneic immunocompetent ID8 ovarian cancer model. Of note, the ID8 murine
ovarian cancer cell lines exhibited CRAd-mediated cytolysis. The use of this model now enables the rational design
of oncolytic agents to achieve anti-tumor immunotherapy.
Conclusions: Limits of widely employed murine xenograft models of ovarian cancer limit their utility for design
and study of armed CRAd virotherapy agents. The ID8 model exhibited CRAd-induced oncolysis. This feature
predicate its potential utility for the study of CRAd-based virotherapy agents.
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Background
Virotherapy is a targeted therapy which has been applied
to carcinoma of the ovary [1, 2]. In this strategy, a virus
is engineered to replicate selectively in tumor target cells
while sparing normal tissues. This selectively of replica-
tion thereby induces targeted tumor cell killing, a
process termed “oncolysis”. To this end, a range of vi-
ruses have been engineered as virotherapy agents includ-
ing Herpes Simplex virus, polio virus, measles virus,
adenovirus, and others [3–6]. Of note, a disproportion-
ate number of virotherapy interventions in humans have
been applied for the context of cancer of the ovary,
reflecting pharmacologic advantages which accrue the
possibility of intraperitoneal delivery.
We have pursued a strategy of virotherapy for ovarian
cancer exploiting adenovirus [7–9]. In this regard, the
unique molecular plasticity of adenovirus has allowed us
to modify native viral tropism to accomplish target cell
infection via over-expressed tumor markers [10, 11].
Specifically, we have developed a conditionally replica-
tive adenoviral agent (CRAd) with the integrin-binding
peptide RGD4C incorporated at the capsid fiber binding
protein [12]. This modified virus can thus infect targets
via integrins recognized by the capsid incorporated
RGD4C binding motifs. This is especially relevant as
ovarian cancer tumor cells express a paucity of the na-
tive adenovirus receptor coxsackie-and-adenovirus re-
ceptor (CAR) [13, 14]. The capacity to accomplish
“CAR-independent” infection circumvents tumor cell
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resistance to adenovirus infection thereby dramatically
improving the oncolytic potency of our advanced gener-
ation CRAd agents [15]. Of note, we have carried-out a
Phase I human clinical trial with our infectivity en-
hanced CRAd, Delta-24-RGD, and demonstrated its
safety as well as its virologic efficacy [16].
More recently, it has been shown that virotherapy
agents may achieve anti-tumor activities over-and-above
their direct oncolytic effects. Specifically, it appears that
virus-mediated oncolysis may represent an effective
means to induce anti-tumor immunization [17–19]. A
number of recent studies have sought to define the bio-
logic basis of this vaccine effect [20, 21]. In addition,
strategies to exploit this biology have been incorporated
into virotherapy agent design. For adenovirus-based vir-
otherapy agents, this has involved “arming” the CRAd
with an immunomodulatory molecule (ex. GM-CSF,
IL-12) in an effort to optimize immunologic milieu to
enhance CRAd-based anti-tumor immunization [22–24].
Despite the novel opportunities offered by this ap-
proach, full development is currently limited by the lack
of models that allow full characterization of CRAd-based
anti-tumor immunization. In this regard, studies of CRAd
interventions for cancer of the ovary have been endeav-
ored almost exclusively in orthotopic human tumor xeno-
graft models [25]. This is owing to the fact that
cross-species factors have been understood to limit pro-
ductive infection by human adenovirus of murine target
cells. On this basis, it has heretofore not been feasible to
exploit syngeneic immunocompetent murine cancer
models to study CRAd-based anti-tumor immunization.
Very recently, however, it has been recognized that the
biologic block to human adenovirus replication in mur-
ine cells is not absolute; human adenovirus can achieve
some level of binding, entry, and post-entry replication
in selected murine targets [25, 26]. On this basis, investi-
gative groups have re-visited the utility of syngeneic im-
munocompetent murine models to gain insight into the
anti-tumor immunizing potentials of adenoviral vir-
otherapies [27–29]. Most recently, Jiang et al. have
found that the murine glioma cell line GL261 could sup-
port limited CRAd-based replication and oncolysis. On
this basis they were able to exploit an immunocompe-
tent murine model of glioma and gain key insights
into CRAd-based anti-tumor immunization [30].
Other recent reports have also exploited murine cell
lines moderately permissive for human adenovirus
replication to employ in corresponding immunocom-
petent murine models of cancer for studies of
CRAd-induced anti-tumor immunization [31, 32].
These new understandings of the utilities of immuno-
competent murine models now potentially provide a
rational pathway to design CRAd agents fully exploit-
ing tumor immunobiology.
On the basis of these considerations, we have sought
to advance an ovarian cancer CRAd design strategy
based upon immunobiologic arming methods. Despite
the fact that we could design and rescue CRAds with
immunobiologic arming molecules, little augmentation
in anti-tumor activity was noted in standard orthotopic
xenograft models of ovarian cancer. On this basis we
have sought to establish the possibility of exploiting
available syngeneic immunocompetent murine models
of cancer of the ovary. In this report we demonstrate
that the widely available ID8 model of ovarian cancer
supports adenovirus-mediated cytolysis, a key attribute
allowing its potential employ for study of CRAd agents
engineered to exploit tumor immunobiology. This syn-
geneic immunocompetent model now can be explored
to allow rational design of CRAd agents for the achieve-
ment of optimal anti-cancer immunotherapy via oncoly-
tic virotherapy.
Methods
Cells
The human ovarian carcinoma cell line SKOV3.ip1 was
obtained from Janet Price (M. D. Anderson Cancer Cen-
ter, Houston, Tex.). The mouse epithelial ovarian cancer
cell line ID8, which was originally established by Dr.
Kathy Roby (Kansas University Medical Center) and its
derivative expressing firefly luciferase were obtained
from Dr. Robin Bachelder (Duke University Medical
Center) and were maintained in DMEM (high glucose,
Gibco-Life Technologies) containing 4% FBS, 1× penicil-
lin and streptomycin as described elsewhere [33]. The
ID8-Trp53−/− [34] mouse ovarian surface epithelial cells
(F3) were kindly provided by Dr. Iain McNeish (Univer-
sity of Glasglow) and labeled to express mCherryLucifer-
ase (F3mCherryLuc). Both cell lines were grown in
DMEM (high glucose, Gibco-Life Technologies) contain-
ing 4% FBS, 1× penicillin and streptomycin and 1× ITS
(Insulin-Transferrin-Selenium solution) (Gibco-Life
Technologies). The 911 human embryonic retinoblasts
derived by transformation with a plasmid containing
79–5789 bp of the Ad5 genome [35] were obtained
through Crucell Holland B.V. (Leiden, The Netherlands).
The human lung carcinoma cell line A549 were obtained
from American Cell Type Culture Collection (ATCC,
Manassas, Virginia USA). All cell lines were grown at 37
°C in medium recommended by the suppliers in a hu-
midified atmosphere of 5% CO2.
CRAd vectors
The replication-competent CRAd Delta 24 was provided
by Dr. J. Fueyo. (The University of Texas M. D. Ander-
son Cancer Center, Houston, TX). This virus contains a
24-nucleotide deletion, from Ad5 bp 923 to 946 (both
included), corresponding to the amino acid sequence
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L122TCHEAGF129 of the E1A protein known to be ne-
cessary for Rb protein binding [36]. Details of the
tumor-specific replication of this virus are presented
elsewhere [37, 38]. The incorporation of the RGD-4C
motif, known to interact with αv integrins, into the HI
loop of the fiber knob (T546CDCRGDCFCP547) to en-
hance Delta24 CRAd infection efficiency of tumor cells
was described previously [15, 39]. The construction of
Ad5/3-Delta24 CRAd, which contains the fiber knob do-
main replaced with its counterpart from Ad serotype 3
(Ad3) was described elsewhere [9, 40]. The construction
of Ad5/3-Delta24-based CRAd-IL24 and CRAd-ING4
vectors expressing human IL-24 [41] or ING4 (the in-
hibitor of growth 4) [42] gene, respectively, under tran-
scriptional control of human cytomegalovirus (CMV)
immediate-early promoter/enhancer incorporated in
place of the deleted E3B region was described in detail
recently [43]. Non-armed control CRAd that encodes
the secreted Gaussia luciferase (Gluc) from the copepod
Gaussia princeps (New England BioLabs Inc., Ipswich,
MA USA) driven by CMV promoter in place of E3B re-
gion was described recently [43]. Wild-type Ad5 was
kindly provided by Dr. H Ugai (Washington University
in St Louis, St Louis, MO).The replication incompetent
Ad5ΔE1 containing the CMV promoter-driven firefly lu-
ciferase reporter gene in place of the deleted E1A/B
genes was described before [44] and propagated using
911 cells. All CRAd vectors and wild type Ad5 were
propagated using A549 cells, purified by centrifugation
on CsCl gradients according to standard protocol, and
dialyzed against phosphate-buffered saline (PBS) (8 mM
Na2HPO4, 2 mM KH2PO4 [pH 7.4], 137 mM NaCl, 2.7
mM KCl] containing 10% glycerol. The titers of physical
viral particles (vp) were determined by the methods of
Maizel et al. [45]. The titers of infectious viral particles
were determined by plaque assay using 911 cells as de-
scribed by Mittereder et al. [46].
Analysis of virus-mediated cytotoxicity in vitro
To monitor cytotoxic effects induced by Ad5, Delta-24,
or Delta-24-RGD vector the cell monolayers grown in
96-well plates (3 × 103 to 5 × 103 cells/well) were infected
in triplicates with each virus at MOI of 100 vp/cell. The
infected and mock-infected cells were subjected to Cell-
Tox™ Green Cytotoxicity assay as recommended by the
manufacturer (Promega Corporation, Madison, WI) by
adding DNA-binding cyanine dye on day 1 and monitor-
ing the increase in fluorescent signal intensity, which is
proportional to cell lysis, till day 5–6 post-infection. The
degree of virus-mediated cell killing was measured using
the Synergy-HT plate reader (Bio-Tek Instruments, Wi-
nooski, VT) equipped with 485 nm excitation and 520
nm emission wavelength filters and the average values of
relative fluorescent units (RFU) are shown. The relative
cell viability on day 5–6 post-infection with either Ad5,
Delta-24, Delta-24-RGD or non-replicating Ad5ΔE1
control was determined using the Cell Proliferation
Assay (Promega Corporation, Madison, WI) as recom-
mended by the manufacturer. Assay was performed by
adding 10 μL CellTiter 96 AQueous One Solution Reagent
directly to culture wells containing red phenol free
media supplemented with 2% FBS, incubating for 2 h
and then recording the absorbance at 490 nm with a
plate reader (Synergy HT, Bio-Tek Instruments, Winoo-
ski, VT). The data are presented as the percentages of
viable cells in monolayers infected with each viral dose
that were determined with respect to the uninfected
control set as 100%.
S.C. Tumor xenograft model
Female 5–7 week-old athymic nu/nu mice (The Jackson
Laboratory) were kept under pathogen-free conditions
according to the American Association for Accreditation
of Laboratory Animal Care guidelines. Animal protocols
were reviewed and approved by the Institutional Animal
Care and Use Committee of the Washington University
in Saint Louis, School of Medicine. Five million SKO-
V3.ip1 cells were xenografted s.c. into the right flank of
the mice under anesthesia. When the nodules reached a
volume of 60–70mm3, a single Ad dose (1010 vp in 20 μl
of PBS) or the same volume of PBS was administered
intratumorally (n = 9–10 animals/group) and injections
were repeated weekly for 3 consecutive weeks. Tumor
size was monitored twice a week, and fractional volume
was calculated by standard technique for volume deter-
mination of subcutaneously xenografted tumors in vivo
using external caliper measurements and the modified
ellipsoid formula 1/2 (Length × Width2) [47, 48]. Animal
were euthanized according to IACUC policy “Maintain-
ing Tumors in Rodents Policy” if the tumor became
greater than 2 cm in any dimension or showed clinically
significant cutaneous ulceration.
I.P. Syngeneic orthotopic model
Female 5–7 week-old C57Bl/6 mice (The Jackson La-
boratories) were injected i.p. with 5 × 106 F3mCherryLuc
cells in 200 μL PBS. After one week, mice were injected
i.p. with 1 × 1010 vp of wild-type Ad or
replication-incompetent Ad vectors in 100 μL PBS (n =
9). Mice were euthanized after 17 days of tumor inocula-
tion. In vivo bioluminescence imaging was performed on
days 7 and 17 after tumor inoculation on an IVIS Lu-
mina (PerkinElmer, Waltham, MA; Living Image 3.2, 1 s
exposure(s), 8 bin. Mice were injected intraperitoneally
with D-luciferin (150mg/kg in PBS; Gold Biotechnology,
St. Louis, MO) and imaged using isoflurane anesthesia
(2% vaporized in O2). Total photon flux (photons/sec)
was measured from fixed regions of interest (ROIs) over
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the entire mouse abdomen using Living Image 2.6. Ani-
mal protocols were reviewed and approved by the Insti-
tutional Animal Care and Use Committee of the
Washington University in Saint Louis, School of
Medicine.
Statistical analysis
All data are presented as the mean ± SD. The Student’s
two-tailed t-test was used to determine statistical signifi-
cance at the 95% confidence level, with p ≤ 0.05 being
considered significantly different for in vitro data. The
animal survival data from the tumor xenograft model
were analyzed using product-limit method to estimate
the survival function S(t) for each treatment and control
group with IBM-SPSS statistics software. The long rank
test with family-wise significance level α = 0.05 was
employed to compare animal survival between control
group treated with non-armed CRAd and each armed
CRAd treatment group. Mann-Whitney test was used to
determine statistical significance in the syngeneic ortho-
topic model groups with non-parametric distribution,
with p ≤ 0.05 being considered significantly different for
the syngeneic orthotopic model.
Results
Anti-tumor effects of armed CRAd agents in murine
xenograft model of carcinoma of the ovary
We have advanced the development of advanced gener-
ation CRAd agents which embody the capacity to ac-
complish CAR-independent infection of tumor cell
targets for enhanced oncolytic potency. Infectivity en-
hancement was initially embodied into CRAd design via
incorporation of the integrin-binding peptide RGD-4C
in the HI loop of the fiber knob [49, 50]. We next pur-
sued a strategy of chimerism for the fiber knob by re-
placing the CAR-binding adenovirus serotype 3 fiber
knob with the corresponding fiber knob domain of the
human adenovirus serotype 3 [9, 40]. Our studies con-
firmed that this latter strategy also allowed significant
enhancement of oncolytic potency in murine orthotopic
xenograft models of ovarian cancer virotherapy. On the
basis of these findings, we sought to advance the design
of our knob 3 infectivity-enhanced CRAd via an “arm-
ing” strategy. Specifically, we sought to configure within
the adenovirus genome the immunoregulatory molecules
ING and IL-24.
On this basis we constructed Ad5/3-Delta24 CRAds
armed with either ING4 or IL-24 [43]. These earlier
studies confirmed that the armed CRAds expressed the
encoded arming genes at a high level. Importantly,
modification of the Ad5/3-Delta24 CRAds in this man-
ner was not deleterious to their anti-tumor oncolytic
properties. We thus evaluated these armed CRAds in an
established murine orthotopic xenograft model of
human cancer of the ovary which employed the human
ovarian cancer cell line SKOV3.ip1. Analysis of treated
animals was endeavored for tumor growth and sur-
vival. As can be seen, the armed versions of Ad5/
3-Delta24 CRAd exhibited less anti-tumor activity
than the parental agent. Importantly, this observation
was noted with both assays of tumor growth (Fig. 1a)
and survival (Fig. 1b).
Cytotoxicity induced by replication-competent human
adenovirus
The findings noted in our study of the armed Ad5/
3-Delta24 CRAds in the murine orthotopic xenograft
model highlighted the limits of immunodeficient models
for analysis of the immunobiologic activities of
adenovirus-based virotherapy agents. To address this
limit, we considered the potential utility of the murine
immunocompetent syngeneic ID8 model of human car-
cinoma of the ovary. Of note, an expanding repertoire of
reports have recently highlighted the utility of this model
for study of ovarian cancer immunobiology. More im-
portantly, this model has demonstrated utility for ana-
lysis of immunotherapy interventions for cancer of the
ovary [51].
As noted, a number of recent reports have reported
the utility of immunocompetent murine models to study
the ability of CRAds to accomplish effective anti-tumor
immunization [29, 30]. Whereas not fully permissive for
productive human adenovirus replication, selected mur-
ine tumor cells targets appear to allow a level of human
adenovirus replication of sufficient magnitude to activate
anti-tumor immunity in the context of implantation in
corresponding immunocompetent syngeneic murine
models. On this basis, we studied the cytolysis in the
murine cell lines ID8 and ID8luc, which were employed
widely as a murine immunocompetent model of ovarian
cancer [51].
We also employed in these studies the human ovarian
cancer cell line SKOV3.ip1, with the wild type adeno-
virus Ad5 and the armed CRAd agents. These adenovi-
ruses achieved prominent cytotoxic effects in this
replication permissive tumor cancer cell line, as pre-
dicted (Fig. 2). The specificity of this effect was con-
firmed by the lack of toxicity induced by the
replication-incompetent control adenovirus. Of note,
similar effects were noted with analysis of the murine
ovarian cancer cell lines ID8 and ID8luc. Indeed, the
levels of induced tumor cell cytotoxicity were nearly
comparable in the murine targets as noted in the human
tumor targets.
Of note, it has recently been shown that knockout de-
rivatives of ID8 exhibited significant alterations of the
tumor microenvironment and reduced survival, with an
overall closer resemblance with the human disease.
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Although the p53-knockout ID8 derivative cell line, F3,
exhibited a lower virus-induced cytotoxicity and replica-
tion compared to a highly susceptible human cancer
line, A549 (Fig. 3), the levels were comparable to those
obtained with GL261, a mouse murine cell line that has
shown utility as a syngeneic model vis-à-vis induction of
anti-tumor immunization.
Anti-tumor effects of ad in murine syngeneic model of
carcinoma of the ovary
Finally, we evaluated the of fully replication competent
wild type adenovirus effect in a syngeneic murine model
generated by the administration of F3mCherryLuc. Ana-
lysis of treated animals after 7 days of Ad5 injection
showed a significant reduction on luminescence signal
(Fig. 4). The ID8 line, and its derivative, thus exhibited: (1)
a level of permissivity to adenovirus-mediated cytotoxicity
in vitro comparable to GL261, a murine model useful for
study of CRAd-induced anti-tumor immunization, and (2)
susceptibility to adenovirus-mediated oncolysis in vivo.
This initial study thus supports the employment of the F3
syngeneic murine model as a potentially robust system for
the study of the therapeutic effect of CRAds for cancer of
the ovary.
Discussion
Whereas oncolytic virotherapy agents were originally de-
signed to accomplish anti-neoplastic effects directly via
viral replication and cytolysis, it has recently become ap-
parent that they can also elicit potent multimodal im-
munogenic tumor cell death. In this regard, virus
infection in cancer cells releases damage-associated pat-
terns recognized by pattern recognition receptors
expressed on cells of the innate immune system. Activa-
tion of these receptors induces pro-inflammatory cyto-
kines provoking Th1-type immune responses [52–54].
Of note, such induced cytokines up-regulate MHC class
I thereby increasing activity of this antigen presentation
pathway [55]. The recognition of these potent immunos-
timulatory effects of virotherapy agents has led to design
A
B
Fig. 1 Analysis of tumor growth inhibition following armed CRAd administration. Subcutaneous tumor xenografts were established on rear flank
of female nude mice using SKOV3.ip1 cells. Tumor nodules were directly injected with 1010 vp (5 × 108 pfu/dose) of either CRAd-IL24, CRAd-ING4,
CRAd-IL24/ING4 (5 × 109 vp of each armed CRAd), control CRAd or PBS alone on day 7 and injections were repeated weekly for 3 consecutive
weeks. a Mean tumor volume of each group is shown through day 35 after tumor implantation. Each data point represents the cumulative mean
of tumor volumes (mm3) in each group while vertical error bars depict standard deviations. b Kaplan-Meier curves of overall survival of animals
treated with the indicated armed CRAd vectors, non-armed CRAd control, or PBS are shown. Data analysis provides no evidence that survival
experience observed in mice treated with either CRAd-IL24, CRAd-ING4, or CRAd-IL24/ING4 (the indicated armed CRAd vectors) is significantly
different from non-armed CRAd control (n.s.)
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strategies to augment these vaccine effects [56]. Of note,
our CRAd agent, Delta-24-RGD, has been adapted in this
manner and shown to accomplish anti-tumor
immunization in human clinical trials [16, 40, 57]. More
recently, it has been noted that syngeneic immunocompe-
tent murine cancer models can provide an effective system
to ascertain vaccine gains which derive from CRAd agents
[30]. This recognition now allows us to explore the mur-
ine ovarian cancer immunotherapy ID8 model to deter-
mine vaccine utilities that derive from our CRAds.
To this point, the species-specific restriction of human
adenovirus has limited study of CRAds in available syn-
geneic immunocompetent murine cancer models. Spe-
cifically, the limited ability of human adenovirus to
replicate in murine cells represented a practical im-
pediment to study of the immunobiologic effects of
CRAd agents. Efficacy in murine xenograft models,
coupled to toxicology studies in C57BL6 mice, thus
constituted the full translational rationale for human
clinical trials. In these instances, however, the man-
dates of human trial design have not been compatible
with fully testing hypotheses related to CRAd-based
anti-tumor immunization.
A number of efforts have thus been advanced to cir-
cumvent this limit. In this regard, our group has adapted
canine adenovirus type 2 (CAV-2) as a CRAd agent for
study in canine concerns. We reasoned that such a “fully
syngeneic” system would allow us to study CRAd biol-
ogy in a genetically outbred and immunocompetent con-
text with the highest level of analogy to the human
context. Other groups have likewise pursued this ap-
proach and demonstrated its utility in guiding rational
CRAd design [30]. This strategy, however, is limited to
the availability of accrued canine patient cohorts and re-
stricted to tumor types common in dogs. Another ap-
proach is based upon the employment of Syrian Golden
Hamster (SGH). In this instance, the relative permissivity
of SGH cells for human adenoviral replication provides an
immunocompetent context to study replication-linked
biologies relevant to CRAd design. As for the canine ap-
plication, however, the limited cancer types available in
the SGH model has limited wide application of this
method.
Recently it has become apparent that the species re-
striction of human adenovirus is not absolute. In this re-
gard, murine cells have been shown to support variable
A
B
Fig. 2 Analysis of cytopathic effects of replication competent Ad vectors. a Cytotoxic effects of wild type Ad5, Ad5-based Delta-24 and Delta-24-
RGD CRAd vectors were compared in established ovarian cancer cell lines of human (SKOV3ip.1) and mouse (ID8 and ID8luc) origin using
CellTox™ assayat the MOI of 100 vp/cell as compared to mock-infected cells (negative control) and completely lysed cells (positive assay control).
Each data point represents the three replicate experiments ± SD (error bars are smaller than the symbols, p ≤ 0.05 *). b Monolayers of SKOV3ip.1,
ID8, and ID8luc were infected with indicated Ad vectors and cell viability determined on day 6 post-infection by adding CellTiter 96 AQueous One
Solution Reagent. The percentages of live cells in the monolayers exposed to replication-deficient E1-deleted Ad5ΔE1 are shown as compared to
wild type Ad5, Delta-24, and Delta-24-RGD-infected cells
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Fig. 4 Analysis of tumor growth inhibition on a syngeneic orthotopic model following Ad administration. C57Bl/6 mice were injected i.p. with
5 × 106 F3mCherryLuc cells. After one week, mice were injected i.p. with 1 × 1010 vp of wild-type Ad or replication-incompetent Ad vectorsBLI
images and corresponding signal quantification 6 days after Ad administration. Significant differences were found between PBS and AdWT groups
(p = 0.0001 ****)
Fig. 3 Analysis of cytopathic effects of replication competent Ad vectors. a Cytotoxic effects of wild type Ad5 were compared in A549, GL261
and F3 using CellTox™ assay. Each data point represents the cumulative mean of triplicate measurements ± SD (p ≤ 0.05 *). b Monolayers of
A549, GL261 and F3 were infected with indicated Ad vectors and cell viability measured after 5 days by adding CellTiter 96 AQueous One Solution
Reagent. The percentages of live cells in the monolayers exposed to replication-deficient E1-deleted Ad5ΔE1 are shown as compared to wild type
Ad5-infected cells. c Replication was assed 48 h after infection at MOI 100vp/cell and 1000vp/cell using the Adeno-X-Rapid Titer kit. Final titers
were determined at pfu/mL (p ≤ 0.05 *)
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levels of binding, entry, and replication of human adeno-
virus. In selected indices, the full cycle of adenoviral rep-
lication can be achieved, albeit at lower levels than
noted for fully permissible immortalized human cancer
cell lines, such as HeLa and A549. Capitalizing on this
recognition, groups have begun to apply human
adenovirus-based CRAds in syngeneic immunocompe-
tent murine cancer models. These reports clearly stab-
lished that, in spite of the lower levels of adenovirus
replication, clear anti-tumor immunization effects could
be accomplished. Most importantly, these CRAd reports
validated the link between CRAd replication and the
agents’ vaccine effect. These observations now provide
the possibility of exploiting such widely available murine
cancer models to guide the design of CRAds for opti-
mized anti-tumor immunization.
These considerations led us to consider the ID8 model
of ovarian cancer to guide design and analysis of ovarian
cancer CRAds. As noted, study of CRAds for cancer of
the ovary has heretofore been endeavored exclusively in
murine xenograft models. In this regard, the ID8 model
represents a syngeneic immunocompetent model of car-
cinoma of the ovary with a human-like clinical presenta-
tion. These properties have led to its employ for a wide
range of studies of tumor immunobiology and
anti-cancer immunotherapies. In our current study we
show ID8 supports human adenovirus mediated tumor
cytolysis. This capability has been shown to be necessary
and sufficient in a number of recent reports to allow
study of CRAd-based anti-tumor immunization in other
syngeneic immunocompetent murine cancer models. In
addition, adenovirus-induced tumor cytolysis can ac-
complish a therapeutic effort in an orthotopic model
context. We would note that the distinct delivery man-
dates of cancer of the ovary may present distinct barriers
from those addressed in earlier studies of CRAds-based
immunization in murine syngeneic models. Specifically,
in these earlier studies CRAds were administered by dir-
ect intratumoral administration and with multiple dos-
ing schemes. These protocols may have facilitated
effective tumor cell cytolysis in vivo based in the high
local levels of the CRAd agent achieved. For cancer of
the ovary, the mandated intraperitoneal delivery schema
may not allow comparable levels of tumor cell infection.
These delivery barriers must be considered in the design
of studies to ascertain anti-tumor immunization exploit-
ing this model.
In the aggregate, the validation of these key feasibilities
now rationalizes the use of this model to explore the full
anti-tumor immunizing potential of the virotherapy ap-
proach for carcinoma of the ovary.
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